CN108066683A - Application of the galangal in the drug or health products for preparing the gastric ulcer that prevention and treatment non-steroidal anti-inflammatory drugs triggers - Google Patents
Application of the galangal in the drug or health products for preparing the gastric ulcer that prevention and treatment non-steroidal anti-inflammatory drugs triggers Download PDFInfo
- Publication number
- CN108066683A CN108066683A CN201810072295.1A CN201810072295A CN108066683A CN 108066683 A CN108066683 A CN 108066683A CN 201810072295 A CN201810072295 A CN 201810072295A CN 108066683 A CN108066683 A CN 108066683A
- Authority
- CN
- China
- Prior art keywords
- galangal
- steroidal anti
- gastric ulcer
- drug
- inflammatory drugs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 244000062241 Kaempferia galanga Species 0.000 title claims abstract description 70
- 235000013421 Kaempferia galanga Nutrition 0.000 title claims abstract description 70
- 239000003814 drug Substances 0.000 title claims abstract description 36
- 229940079593 drug Drugs 0.000 title claims abstract description 34
- 208000007107 Stomach Ulcer Diseases 0.000 title claims abstract description 33
- 201000005917 gastric ulcer Diseases 0.000 title claims abstract description 33
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 title claims abstract description 21
- 238000011282 treatment Methods 0.000 title claims abstract description 20
- 230000002265 prevention Effects 0.000 title claims abstract description 17
- 230000036541 health Effects 0.000 title claims description 13
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims abstract description 42
- 229960000905 indomethacin Drugs 0.000 claims abstract description 21
- 239000000284 extract Substances 0.000 claims description 47
- VCCRNZQBSJXYJD-UHFFFAOYSA-N galangin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=CC=C1 VCCRNZQBSJXYJD-UHFFFAOYSA-N 0.000 claims description 44
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- CIPSYTVGZURWPT-UHFFFAOYSA-N galangin Natural products OC1=C(Oc2cc(O)c(O)cc2C1=O)c3ccccc3 CIPSYTVGZURWPT-UHFFFAOYSA-N 0.000 claims description 19
- SUYJZKRQHBQNCA-UHFFFAOYSA-N pinobanksin Natural products O1C2=CC(O)=CC(O)=C2C(=O)C(O)C1C1=CC=CC=C1 SUYJZKRQHBQNCA-UHFFFAOYSA-N 0.000 claims description 19
- 239000000469 ethanolic extract Substances 0.000 claims description 16
- 244000141218 Alpinia officinarum Species 0.000 claims description 7
- 239000001774 alpinia officinarum Substances 0.000 claims description 7
- 230000002829 reductive effect Effects 0.000 claims description 7
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 5
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 5
- 230000000977 initiatory effect Effects 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 3
- 150000002475 indoles Chemical class 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 2
- 230000003637 steroidlike Effects 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 27
- 230000006378 damage Effects 0.000 abstract description 20
- 230000002496 gastric effect Effects 0.000 abstract description 14
- 210000001156 gastric mucosa Anatomy 0.000 abstract description 12
- 238000002474 experimental method Methods 0.000 abstract description 11
- 230000014509 gene expression Effects 0.000 abstract description 7
- 230000015572 biosynthetic process Effects 0.000 abstract description 6
- 238000003786 synthesis reaction Methods 0.000 abstract description 6
- 230000017531 blood circulation Effects 0.000 abstract description 5
- 230000035876 healing Effects 0.000 abstract description 5
- 230000028327 secretion Effects 0.000 abstract description 4
- 229920000715 Mucilage Polymers 0.000 abstract description 3
- 239000000853 adhesive Substances 0.000 abstract description 3
- 210000000440 neutrophil Anatomy 0.000 abstract description 3
- 238000011084 recovery Methods 0.000 abstract description 2
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 abstract 1
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 235000019441 ethanol Nutrition 0.000 description 20
- 241000700159 Rattus Species 0.000 description 15
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 12
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 12
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 12
- 102100036201 Oxygen-dependent coproporphyrinogen-III oxidase, mitochondrial Human genes 0.000 description 11
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 11
- 208000025865 Ulcer Diseases 0.000 description 11
- 108030001679 Endothelin-converting enzyme 1 Proteins 0.000 description 10
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 10
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 10
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 10
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 10
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 9
- 210000002784 stomach Anatomy 0.000 description 9
- 231100000397 ulcer Toxicity 0.000 description 9
- 238000001514 detection method Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 102100029112 Endothelin-converting enzyme 1 Human genes 0.000 description 7
- 102100021079 Ornithine decarboxylase Human genes 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 5
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 102100021022 Gastrin Human genes 0.000 description 4
- 108010052343 Gastrins Proteins 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- KZFDVWZZYOPBQZ-UHFFFAOYSA-K bismuth;potassium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [K+].[Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KZFDVWZZYOPBQZ-UHFFFAOYSA-K 0.000 description 4
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 4
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- SQFSKOYWJBQGKQ-UHFFFAOYSA-N kaempferide Chemical compound C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 SQFSKOYWJBQGKQ-UHFFFAOYSA-N 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 108010045283 Cystathionine gamma-lyase Proteins 0.000 description 3
- 102000048186 Endothelin-converting enzyme 1 Human genes 0.000 description 3
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 3
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 3
- 108010055012 Orotidine-5'-phosphate decarboxylase Proteins 0.000 description 3
- 102100023536 Solute carrier family 2, facilitated glucose transporter member 1 Human genes 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 229960002986 dinoprostone Drugs 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- MPIAGWXWVAHQBB-UHFFFAOYSA-N [3-prop-2-enoyloxy-2-[[3-prop-2-enoyloxy-2,2-bis(prop-2-enoyloxymethyl)propoxy]methyl]-2-(prop-2-enoyloxymethyl)propyl] prop-2-enoate Chemical compound C=CC(=O)OCC(COC(=O)C=C)(COC(=O)C=C)COCC(COC(=O)C=C)(COC(=O)C=C)COC(=O)C=C MPIAGWXWVAHQBB-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- -1 cNOS Proteins 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- OFTHNFJNLGTFTO-UHFFFAOYSA-N 7-phenylheptan-2-one Chemical compound CC(=O)CCCCCC1=CC=CC=C1 OFTHNFJNLGTFTO-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 102000052812 Ornithine decarboxylases Human genes 0.000 description 1
- 108700005126 Ornithine decarboxylases Proteins 0.000 description 1
- 241000549435 Pria Species 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- YPQJHZKJHIBJAP-UHFFFAOYSA-N [K].[Bi] Chemical compound [K].[Bi] YPQJHZKJHIBJAP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- GDVKFRBCXAPAQJ-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide Chemical group [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O GDVKFRBCXAPAQJ-UHFFFAOYSA-A 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 108010017796 epoxidase Proteins 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 235000019604 hot taste sensations Nutrition 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 208000016752 upper digestive tract disease Diseases 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9062—Alpinia, e.g. red ginger or galangal
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses application of the galangal in the drug for preparing the gastric ulcer that prevention and treatment non-steroidal anti-inflammatory drugs triggers.The present invention is screened by many experiments, the results showed that, galangal can not only be by improving the expression of affected area COX 1,2 albumen of COX so that the PGs contents that downstream generates rise, and participate in the reparation of gastric ulcer damage, promote the recovery of damage；And it can be advanced by leaps and bounds by improving the non COX of affected area and play adjustment effect：And the experimental results showed that：Galangal can also be by promoting CSE, ECE 1, cNOS, iNOD, so as to increase NO and H2The synthesis of S can increase gastric mucosal blood flow, stimulate mucilage secretion, inhibit neutrophil adhesion, promote the reparation and healing of gastric mucosa.Reach and prevent in advance and protect gastric mucosa, prevent the effect of the generation of gastric ulcer, and the later stage can play the double effects of gastric ulcer caused by treating the non-steroidal anti-inflammatory drugs such as Indomethacin.
Description
Technical field
The present invention relates to the new applications of Chinese medicine, and in particular to the stomach that galangal triggers in prevention and treatment non-steroidal anti-inflammatory drugs
Application in ulcer.
Background technology
Non-steroidal anti-inflammatory drugs, such as Indomethacin or aspirin, are widely used in clinic, have good antipyretic-antalgic
And other effects, but non-steroidal anti-inflammatory drugs long-term use can generate the upper digestive tracts adverse reaction such as gastric ulcer, there are significant health
Risk.Non-steroidal anti-inflammatory drugs by the inhibitory action to COX enzymes come block the synthesis of prostaglandin (PGs) be generate digestibility burst
One of mechanism of adverse reactions such as ulcer：Inhibiting COX-1 causes gastric mucosa PGs synthesis to reduce, and stomach can be caused to burst the inhibition of COX-2
Ulcer, but some researches show that the gastric ulcer lesion periphery COX-2 PGs catalyzed and synthesized remarkably promote the healing of ulcer.In addition, NO and
H2S can increase Gastric Mucosa Blood Flow, stimulate mucous secretion, inhibit neutrophil adhesion, safeguard the integrality of stomach lining.Non- steroid
Body anti-inflammatory agent is by inhibiting CSE (Cystathione- γ-lyase), ECE (Endothelin-converting enzyme-1)
Make H with cNOS (Constitutivenitric oxide synthase)2The synthesis of S and NO is reduced, and influences the reparation of stomach lining
And healing.
Galangal conduct《Chinese Pharmacopoeia》In there is warm stomach preventing or arresting vomiting, the medicine simply of eliminating cold to stop pain effect, currently without Gao Liang
Report in the upper digestive tracts adverse reactions such as the gastric ulcer that ginger triggers in prevention and treatment non-steroidal anti-inflammatory drugs.
The gastric ulcer model reported at present has ethyl alcohol gastric injury model, rat water logging straining lasering type model, rat acetic acid damage
Hinder the models such as Ulcer Models, rat pylorus ligation model, Helicobacter pylori infection in mice.
The content of the invention
Goal of the invention：It is an object of the invention to be screened by many experiments, galangal and galangal rhizome extract are studied
New application in the disease of upper digestive tract such as the gastric ulcer triggered in prevention and treatment non-steroidal anti-inflammatory drugs.
Galangal is in the drug or health products for preparing the gastric ulcer that prevention and treatment non-steroidal anti-inflammatory drugs triggers
Using.
Galangal ethanol extract or Galangin are preparing the gastric ulcer disease of prevention and treatment non-steroidal anti-inflammatory drugs initiation
Application in the drug or health products of disease.
Preferably, above-described galangal is preparing the gastric ulcer of prevention and treatment non-steroidal anti-inflammatory drugs initiation
Application in the drug or health products of disease, the non-steroidal anti-inflammatory drugs are Indomethacin or aspirin.
Preferably, above-described galangal ethanol extract or Galangin are preparing the non-steroid of prevention and treatment
Application in the drug or health products of the gastric ulcer that body anti-inflammatory agent triggers, the non-steroidal anti-inflammatory drugs for Indomethacin or
Aspirin.
Preferably, above-described galangal ethanol extract or Galangin are preparing the non-steroid of prevention and treatment
Application in the drug or health products of the gastric ulcer that body anti-inflammatory agent triggers, the preparation side of the galangal ethanol extract
Method is：Weigh Alpinia Officinarum, after crushing, add alcohol reflux extract 1~3 time, every time 1~2 it is small when, merge extracting solution, decompression
Concentration, vacuum drying, obtains galangal ethanol extract.
As more preferred scheme, the preparation method of galangal ethyl alcohol extract is：Alpinia Officinarum is weighed, 10 are added after crushing
80% alcohol reflux of amount volumetric concentration extracts 3 times again, and each 1h is filtered while hot, merges 3 filtrates, is concentrated under reduced pressure into no alcohol taste,
Concentrate is dried in vacuo to obtain galangal alcohol extract.The paste-forming rate 17.6% of extract, Galangin, Kaempferide, 5- in extract
Hydroxyl -7 (4 "-hydroxyl -3 "-methoxyphenyl) -1- phenyl -3- heptanone (DPHA), 7- (4 "-hydroxyl -3 "-methoxyphenyl) -
The weight percentage of the double benzene -3- heptanone (DPHC) of 1- benzene -4- teracrylic acids -one (DPHB), 5- hydroxyls -1,7- is followed successively by
0.88%th, 0.45%, 1.11%, 0.24%, 0.89%.
Advantageous effect：The present invention is screened by many experiments, the experimental results showed that, galangal alcohol extract and Galangin are not
It only can be by improving the expression of affected area COX-1, COX-2 albumen so that the PGs contents that downstream generates rise, and participate in
The reparation of gastric ulcer damage, promotes the recovery of damage；And it can also be made by improving the non-COX of affected area and advancing by leaps and bounds to play to adjust
With：In addition the present invention the experimental results showed that：Galangal ethanol extract and Galangin by promote CSE, ECE-1, cNOS,
INOD, so as to increase NO and H2The synthesis of S, and then gastric mucosal blood flow can be increased, mucilage secretion is stimulated, inhibit neutrophil leucocyte
Adherency, promotes the reparation and healing of gastric mucosa.It may ultimately reach and prevent in advance and protect gastric mucosa, prevent the generation of gastric ulcer
It acts on, and the later stage can play the double effects of gastric ulcer caused by treating the non-steroidal anti-inflammatory drugs such as Indomethacin, obtain
Extraordinary technique effect.
Description of the drawings
Fig. 1 is ulcer index GUI observed result figures.
Fig. 2 is pathological section HE coloration results.
Fig. 3 is Elisa kit testing result figures.
Fig. 4 is COX accesses WB detection figures.
Fig. 5 is non-COX access Elisa testing result figures.
Fig. 6 is ulcer index GUI observed result figures.
Fig. 7 is pathological section HE coloration result figures.
Fig. 8 is Elisa experimental result pictures.
Fig. 9 is Western blot results.
Specific embodiment
With reference to specific embodiment, the present invention is further elaborated, but these embodiments should not be construed as limiting this hair
It is bright.
1 galangal alcohol extract of embodiment and Galangin treatment Indomethacin induced Acute gastric ulcer injury experiment
1st, experiment material：
160-190g SD rats, half male and half female.Indomethacin (Linfen Qi Lin pharmaceutcal corporation, Ltds, lot number：1402151),
1% sodium carboxymethylcellulose is prepared.Galangal ethyl alcohol extract：Alpinia Officinarum 500g is weighed, Alpinia Officinarum weight is added after crushing
80% ethyl alcohol of 10 times of amount volumes of amount, refluxing extraction 3 times, each 1h are filtered, are merged 3 filtrates, be concentrated under reduced pressure into no alcohol while hot
Taste, concentrate are dried in vacuo to obtain galangal alcohol extract.Galangin (Chengdu Puffy moral Bioisystech Co., Ltd, lot number：
16091902), Elisa kits (Suzhou Calvin bio tech ltd).
2nd, experimental method：
Indomethacin Ulceration damages modeling preliminary experiment
70 modelings of SD rats, half male and half female are taken, Rat Fast be can't help water and be stayed overnight, and early 9:00 gavage rat Indomethacin
30mg/kg.After continuing fasting 7h, 10 rats (half male and half female) are randomly selected, 7% chloraldurate (0.5ml/ is injected intraperitoneally
It 100g) anaesthetizes, abdominal vein takes blood to put to death, and -80 DEG C of preservations of centrifuging and taking blood plasma are to be measured.Stomach is taken, is cut off along greater curvature, with 0.9%
Physiological saline washes away gastric content, puts observation gastric mucosa damage situation under 10 times of surgical operation microscopes, determines modeling success.Then put
It is fixed in 4% formalin.
After modeling detects successfully, remaining mouse is randomly divided into 6 groups, every group of 10 rats, half male and half female is respectively model
Group, galangal alcohol extract high dose group (0.18g/kg), galangal alcohol extract middle dose group (0.09g/kg), galangal alcohol extract
Low dose group (0.03g/kg), Galangin group (200mg/kg) and Hydrotalcite group (0.88g/kg).Every group for the treatment of group is daily
Early 9:00 is administered once by metering, separately randomly selects 10 rats, and half male and half female is blank group.Blank group and model group are daily
Give 1%CMC-Na.
Medication：The morning：9:00-10:00 gastric infusion, afternoon：12:00-5:00 to food, evening：It was deprived of food but not water
Night.Successive administration observes animal feed and defecation situation daily, and administration number of days is determined with this.
7% chloraldurate (0.5ml/100g) anesthesia is injected after 1h is administered in last time, abdominal vein takes blood to put to death, from
The heart takes -80 DEG C of preservations of blood plasma to be measured.Stomach is taken, is cut off along greater curvature, gastric content is washed away with 0.9% physiological saline, puts 20 times of hands
The micro- Microscopic observation gastric mucosa damage situation of art, takes pictures, record ulcer index (1mm counts 1 point).4% first of a part of gastric tissue
Aldehyde solution is fixed, and carries out HE staining analysis.Remaining -80 DEG C freeze, by gastric tissue with ice-cold before ELISA kit detection is carried out
0.9% physiological saline be homogenized (1g in proportion:5ml), 3000rpm centrifuges 10min and takes supernatant in 4 DEG C of environment.Using obtaining
The supernatant obtained carries out the Protein Detection of TNF-α, VEGF concentration variation detection and COX and non-COX related pathways.
3rd, experimental result
3.1st, GUI and HE detections
GUI observed results such as Fig. 1.The damage of the results show gastric mucosa is effectively alleviated (p<0.001, Fig.1) high
Rhizoma Alpiniae Officinarum extract shows a kind of concentration gradient effect, and GUI indexes fall below high dose from the 20.23 ± 1.38 of model group
The 1.66 ± 0.37 of group.In addition, the high, galangal rhizome extract of middle dose group is better than positive drug to the remission effect of gastric mucosa damage
Object group (p<0.001).
HE coloration results are shown in Fig. 2.High, the galangal rhizome extract group of middle dosage and Galangin group conspicuousness reduce HE
Index (p<0.001,p<0.05,p<0.05and p<0.05,).Equally, galangal rhizome extract also shows in HE index results
A kind of concentration gradient interactively is gone out.By the effect of high dose galangal rhizome extract, HE indexes from the 4.67 of model group ±
1.03 fall below 0.33 ± 0.51, in addition, galangal rhizome extract high dose group is better than positive drug to the effect of HE indexes
Group (p<0.05).
GUI and HE indexes detection the result shows that：Galangal rhizome extract and Galangin can obviously relieve Indomethacin and make
Into rat pipe film injury.And the effect of the galangal rhizome extract of high dose is better than positive drug bismuth citrate
Potassium.
3.2 Elisa kit testing results
3.2.1 TNF-α and the variation of VEGF concentration in gastric tissue
One-way ANOVA statistical analyses are carried out according to the data obtained, P ＜ 0.05 have conspicuousness.From the figure 3, it may be seen that indoles
After Mei Xin effects, the concentration of TNF-α significantly rises (p<0.05), galangal rhizome extract high dose group and positive drug group difference
The concentration of TNF-α is made to have dropped 14.17% and 11.56% (p<0.05).After drug treatment, three groups of galangal rhizome extract groups
TNF-α concentration with positive drug group is with the TNF-α concentration of control group without statistics difference (Fig. 3 A).
Meanwhile after Indomethacin effect, the concentration of VEGF is remarkably decreased (p<0.05, Fig.3B).After administration is handled,
Each group has been obviously improved VEGF levels.Meanwhile galangal rhizome extract shows the castering action of a positive concentration gradient
(LGE-H:1.57 times, LGE-M:1.51 times, LGE-L:1.43 times, compared with MOD groups, Fig. 3 B, VEGF：Vascular endothelial growth factor
Son).Compared with positive drug group, galangal rhizome extract is high, the VEGF levels under middle dosage effect will be significantly higher than positive drug
Group (p<0.001 and p<0.05).In addition, the horizontal VEGF water for being even above control group of the VEGF of galangal rhizome extract high dose group
Flat (1.23 times, p<0.05).Galangal rhizome extract peomotes gastric ulcer damage to the horizontal remarkable effect effects promoted of VEGF
The angiogenesis of injury, the blood flow of gastric ulcer injury region caused by recovering Indomethacin so that injury region is easier to recover.
3.2.2 COX and non-COX pathway proteins concentration changes in gastric tissue
One-way ANOVA statistical analyses are carried out according to the data obtained, P ＜ 0.05 have conspicuousness.
3.3 COX accesses WB are detected
After Indomethacin modeling, COX-1 and COX-2 levels are suppressed (Fig. 4, COX-1 (epoxidase -1) COX-2
(cyclooxygenase-2)；β-actin (beta-actin, the common internal references of PCR).After administration in 6 days, galangal rhizome extract is high, in
Dosage group, Galangin group and positive drug group have been obviously improved COX-1 expressions, are improved respectively compared with model group
1.25 times of (p<0.001), 1.16 times of (p<0.05), 1.12 times of (p<And 1.25 times of (p 0.05)<0.05).Meanwhile galangal extracts
Object is high, middle dose group, the horizontal no difference of science of statistics (p with control group of the COX-1 of Galangin group and positive drug group>
0.05), show that the COX-1 levels of these groups have had been restored to normal level after administration.In addition, all administration groups
In, only galangal rhizome extract low dose group is less than positive drug group, other groups and positive drug to the impact effect of COX-1 levels
Object group no difference of science of statistics.
Meanwhile after administration in 6 days, galangal rhizome extract high dose group and positive drug group significantly increase COX-2 water
It is flat, compared with model group, 1.14 times and 1.19 times of (p are improved respectively<0.05).
3.4 non-COX accesses Elisa are detected
After Indomethacin acts on, the horizontal rise (4.97 ± 0.08ng/g) of ECE-1 in gastric mucosa, while cNOS and
NO levels be suppressed significantly (be respectively 18.27 ± 0.85U/g and 18.20 ± 0.23 μm of ol/kg) (Fig. 5 A, Fig. 5 B and Fig. 5 C,
In, CSE:Cystathionie-γ-lyases；Ece-1:Endothelin converting enzyme 1；cNOS:Endothelial intrinsic nitric oxide synthase；NO:One
Nitrogen oxide；ODC:Ornithine decarboxylase).After administration acts on, LGE-H groups have been obviously reduced rush of the Indomethacin to ECE-1
Into with the inhibitory action (p to cNOS, NO<0.05).In control group, the average level of ODC and CSE in stomach lining is 3.21
± 0.15ng/g and 18.74 ± 0.35 μm of ol/kg.Indomethacin significantly suppresses the expression (p of the two albumen<0.01, Fig. 5 D
And p<0.05, Fig. 5 E).After 6 days drug treatments, the ODC levels that each group is administered are significantly reduced (Fig. 5 D), wherein LGE-H
With the horizontal no difference of science of statistics (p with control group of the ODC in LGE-M groups>0.05) the CSE levels in .LGE-H and POS groups
By notable up-regulation (p<0.05).
2 galangal ethanol extract of embodiment and Galangin test the prevention and protective effect of gastric ulcer
1st, experiment material
180-220g SD rats, half male and half female.Indomethacin (Linfen Qi Lin pharmaceutcal corporation, Ltds, lot number：1402151),
1% sodium carboxymethylcellulose is prepared.Galangal ethyl alcohol extract：Alpinia Officinarum 500g is weighed, Alpinia Officinarum is added in after crushing
10 times of 80% alcohol refluxs of volume of weight extract 3 times, and each 1h is filtered while hot, merge 3 filtrates, are concentrated under reduced pressure into no alcohol
Taste, concentrate be dried in vacuo galangal alcohol extract (paste-forming rate 17.6%, Galangin, Kaempferide, DPHA, DPHB, DPHC contain
Amount successively be about 0.88%, 0.45%, 1.11%, 0.24%, 0.89%).(Chengdu Puffy moral biotechnology is limited for Galangin
Company, lot number：16091902), ABcam antibody：COX-1, COX-2, ODC, CSE, iNOS, cNOS, ECE-1 (USA).
2nd, experimental method
2.1st, 42 SD rats (half male and half female) are randomly divided into blank group (CON), galangal ethanol extract low dosage
Group (LGE-L, 0.09mg/kg), galangal ethanol extract middle dose group (LGE-M, 0.18g/kg), galangal ethanol extract
High dose group (LGE-H, 0.36g/kg), Galangin group (GAL, 200mg/kg), Bismuth Potassium Citrate group (POS, 80mg/kg) and
Model group (MOD), every group 6.The administration evening before yesterday 9 every time:00 fasting, next day early 9:00 administration, administration 4 it is small when after feed, continuously
Administration 15 days.It is deprived of food but not water after last day administration, that night 9:00 gives Indomethacin 30mg/kg manufacture gastric ulcer models,
Except blank group.Second day early 9:00 abdominal vein takes blood to put to death, and 3000rpm centrifuges the blood that 10min is obtained in 4 DEG C of environment
Slurry.Elisa experiments are carried out using the blood plasma of acquisition, for TNF-α, gastrin (GAS), NO, PGE2、H2S and IL-1 concentration changes
Detection.Meanwhile detection obtains rat gastric tissue, and stomach is dissected and observed, and detects gastric ulcer degree of impairment, records data,
Divide per 1mm ulcerative lesions meter 1.A gastric tissue part for acquisition is stored in 4% formalin fixed, progress pathological section analysis；
Another part freezes in -80 DEG C, remains subsequently to COX-1, COX-2, ODC, CSE, iNOS, cNOS, ECE-1 carry out albumen and base
Because level detects.
2.2、Western blot
The preparation of tissue sample
The gastric tissue that every rat freezes is taken into 0.1g, adds in 500 microlitres of PRIA lysates (Thermo companies, containing 4.8%
PMSF solution), it is homogenized on ice using distributing refiner, is repeated several times to solution being suspended homogeneous, it is small in standing one on ice
When.4 DEG C afterwards, 12000rpm is centrifuged 5 minutes, takes supernatant.Using the protein concentration of BCA kits detection albumen homogenate, make
Unify Supernatant protein concentration with RIPA lysates.Add in 5X sample-loading buffers (containing beta -mercaptoethanol), boiling water bath 5 minutes.It
12000rpm is centrifuged 5 minutes afterwards, is taken supernatant, is transferred in the test tube of another cleaning, so far, electrophoresis Sample is ready for ready
(sample can be frozen using can also also dispense immediately, and the samples of -20 DEG C of storages, which can be stablized, is kept for the several months.)
Western blot are tested
Electrophoresis is carried out using the SDS-PAGE of 10% separation gel, separates total extraction albumen.Use Bio-rad mini transferring films
After instrument carries out transferring film, protein blocking is carried out with 5%milk or 5%BSA.Primary antibody is carried out then according to the primary antibody specification of each albumen
It is incubated with secondary antibody, develops after washing.The experiment condition of specific each albumen see the table below.
3rd, experimental result
3.1 substantially observe ulcer index result
It will be appreciated from fig. 6 that after continuous protectiveness administration in 15 days, galangal rhizome extract and Galangin can be apparent
Damage of the mucosa tissue away from Indomethacin is protected, wherein being shown with galangal rhizome extract a kind of as concentration variation is in
The drug action of curvilinear characteristic, the protective effect of middle dose group are most strong.In addition, Galangin equally also does well.
3.2 pathological section results
As shown in Figure 7, after the protectiveness administration of continuous 15 days, pathological section shows galangal rhizome extract and galangal
Element has mucosa tissue preferable protective effect.
3.3 Elisa experimental results
By Fig. 8 (wherein GAS：Gastrin；PGE2：Prostaglandin E2；TNFα：Huamn tumor necrosis factory alpha；IL-1：Bai Jie
Element -1；NO：Nitric oxide；H2S：Hydrogen sulfide) it understands, after the protectiveness administration of continuous 15 days, galangal rhizome extract and height
Galingal, which is known as, reverses Indomethacin to Gas, PGE2, TNF-α, IL-1 β, NO and H in blood plasma2The effect of S expressions effect.Its
Middle galangal rhizome extract shows a kind of drug action for changing curved feature with concentration, the protective effect of middle dose group
It is most strong.In addition, the middle and high dosage group of galangal rhizome extract is better than positive drug Bismuth Potassium Citrate to the effect of TNF-α.
3.4 Western blot results
As shown in Figure 9, after the protectiveness administration of continuous 15 days, galangal rhizome extract and galangal are known as reverse indoles
Mei Xin is to COX-1 in gastric ulcer mucosal tissue, COX-2, ODC, CSE, iNOS, the effect of cNOS and ECE-1 protein expression levels
Effect.Wherein galangal rhizome extract shows a kind of drug action for changing curved feature with concentration, middle dose group
Protective effect is most strong.In addition, the middle and high dosage group of galangal rhizome extract and Galangin group are better than the effect of COX-2
Positive drug Bismuth Potassium Citrate；The middle and high dosage group of galangal rhizome extract is better than positive drug citric acid to the effect of CSE
Bismuth potassium.
Above the experimental results showed that.Galangal alcohol extract and Galangin can not only by improve affected area COX-1,
The expression of COX-2 albumen so that the PGs contents that downstream generates rise, and participate in the reparation of gastric ulcer damage, promote damage
Recover；Also can advance by leaps and bounds performance by improving the non-COX of affected area simultaneously dare to adjustment effect：Galangal ethanol extract simultaneously
With Galangin by the way that CSE, ECE-1, cNOS, iNOD NO, H2S synthesis is promoted to increase, and then increase gastric mucosal blood flow, thorn
Swash mucilage secretion, inhibit neutrophil adhesion, promote the reparation and healing of gastric mucosa.With good preventing gastric ulcer disease
The effect of.
The above is only the preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
For member, various improvements and modifications may be made without departing from the principle of the present invention, these improvements and modifications also should
It is considered as protection scope of the present invention.
Claims (5)
1. galangal answering in the drug or health products for preparing the gastric ulcer that prevention and treatment non-steroidal anti-inflammatory drugs triggers
With.
2. galangal ethanol extract or Galangin are preparing the gastric ulcer of prevention and treatment non-steroidal anti-inflammatory drugs initiation
Drug or health products in application.
3. galangal according to claim 1 is preparing the gastric ulcer of prevention and treatment non-steroidal anti-inflammatory drugs initiation
Application in drug or health products, which is characterized in that the non-steroidal anti-inflammatory drugs is Indomethacin or aspirin.
4. galangal ethanol extract according to claim 2 or Galangin are preparing prevention and treatment non-steroidal anti-inflammatory
Application in the drug or health products of the gastric ulcer of efficacy-enhancing ingredient hair, which is characterized in that the non-steroidal anti-inflammatory drugs is indoles
U.S. pungent or aspirin.
5. galangal ethanol extract according to claim 4 or Galangin are preparing prevention and treatment non-steroidal anti-inflammatory
Application in the drug or health products of the gastric ulcer of efficacy-enhancing ingredient hair, which is characterized in that the galangal ethanol extract
Preparation method is：Weigh Alpinia Officinarum, after crushing, add alcohol reflux extract 1~3 time, every time 1~2 it is small when, merge extraction
Liquid is concentrated under reduced pressure, and vacuum drying obtains galangal ethanol extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810072295.1A CN108066683A (en) | 2018-01-25 | 2018-01-25 | Application of the galangal in the drug or health products for preparing the gastric ulcer that prevention and treatment non-steroidal anti-inflammatory drugs triggers |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810072295.1A CN108066683A (en) | 2018-01-25 | 2018-01-25 | Application of the galangal in the drug or health products for preparing the gastric ulcer that prevention and treatment non-steroidal anti-inflammatory drugs triggers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108066683A true CN108066683A (en) | 2018-05-25 |
Family
ID=62157013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810072295.1A Pending CN108066683A (en) | 2018-01-25 | 2018-01-25 | Application of the galangal in the drug or health products for preparing the gastric ulcer that prevention and treatment non-steroidal anti-inflammatory drugs triggers |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108066683A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112552155A (en) * | 2020-12-23 | 2021-03-26 | 海南医学院 | 1, 7-diphenyl-4-heptylene-3-ketone separated from galangal and application thereof |
| CN112645808A (en) * | 2021-01-05 | 2021-04-13 | 海南医学院 | 5-hydroxy-1, 7-diphenyl-3-heptanone separated from galangal and application thereof |
| CN112898143A (en) * | 2021-01-20 | 2021-06-04 | 海南医学院 | 5-hydroxy-7- (4-hydroxy-3-methoxyphenyl) 1-phenyl-3-heptanone separated from galangal and application thereof |
| CN115006504A (en) * | 2022-06-17 | 2022-09-06 | 海南医学院 | Liangfu extract, extraction and purification process and optimization method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1799616A (en) * | 2005-09-22 | 2006-07-12 | 深圳市东方泰格生物医药有限公司 | Gastric ulcer treatment medicine, its preparation process and application |
| CN105434451A (en) * | 2015-11-18 | 2016-03-30 | 海南医学院 | Two flavonoids compounds for treating gastric ulcer disease |
-
2018
- 2018-01-25 CN CN201810072295.1A patent/CN108066683A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1799616A (en) * | 2005-09-22 | 2006-07-12 | 深圳市东方泰格生物医药有限公司 | Gastric ulcer treatment medicine, its preparation process and application |
| CN105434451A (en) * | 2015-11-18 | 2016-03-30 | 海南医学院 | Two flavonoids compounds for treating gastric ulcer disease |
Non-Patent Citations (2)
| Title |
|---|
| 康爱荣等: ""高良姜中高良姜素的醇提和纯化工艺研究"", 《中国中医药信息杂志》 * |
| 魏娜等: ""高良姜不同提取部位对实验性胃溃疡的影响及作用机理研究"", 《海南医学院学报》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112552155A (en) * | 2020-12-23 | 2021-03-26 | 海南医学院 | 1, 7-diphenyl-4-heptylene-3-ketone separated from galangal and application thereof |
| CN112645808A (en) * | 2021-01-05 | 2021-04-13 | 海南医学院 | 5-hydroxy-1, 7-diphenyl-3-heptanone separated from galangal and application thereof |
| CN112898143A (en) * | 2021-01-20 | 2021-06-04 | 海南医学院 | 5-hydroxy-7- (4-hydroxy-3-methoxyphenyl) 1-phenyl-3-heptanone separated from galangal and application thereof |
| CN115006504A (en) * | 2022-06-17 | 2022-09-06 | 海南医学院 | Liangfu extract, extraction and purification process and optimization method thereof |
| CN115006504B (en) * | 2022-06-17 | 2023-10-31 | 海南医学院 | Liangfu extract, extraction and purification process and optimization method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108066683A (en) | Application of the galangal in the drug or health products for preparing the gastric ulcer that prevention and treatment non-steroidal anti-inflammatory drugs triggers | |
| KR101084105B1 (en) | Composition comprising ursolic acid and oleanolic acid for protecting and treating arthritis | |
| KR101863604B1 (en) | Composition for preventing, improving or treating hyperuricemia or metabolic disorders associated with hyperuricemia comprising extract of Alpiniae fructus as effective component | |
| CN104248666A (en) | Compositions for preventing or improving gastrointestinal diseases | |
| KR102567235B1 (en) | Composition for the prevention and treatment of Inflammatory Bowl Disease | |
| KR101725912B1 (en) | The Pharmaceutical composition for the prevention and treatment of diabetic complications and angioedema comprising natural mixture extracts | |
| CN105338993A (en) | Composition for preventing, relieving or treating colitis, containing complex extracts | |
| KR101791034B1 (en) | Composition for preventing, improving or treating hyperuricemia or metabolic disorders associated with hyperuricemia comprising extract of Allii Radix as effective component | |
| Cianci et al. | T-tube biliary drainage during reconstruction after pancreaticoduodenectomy. A single-center experience | |
| CN105287812A (en) | Medicine composition for treating irritable bowel syndromes and application of medicine composition | |
| CN105687422B (en) | Raspberry composition and application thereof | |
| CN111920908A (en) | Pharmaceutical composition for treating peptic ulcer | |
| CN102370884B (en) | Chinese medicinal composition for treating epigastric pain and preparation method thereof | |
| CN101461831B (en) | Geranium extract | |
| US9457055B2 (en) | Method for treating inflammation, arthritis or disc diseases using a mixed extract of cibotii rhizoma, ledebouriellae radix, achyranthis radix, paeonia lactiflora pall and glycyrrhizae radix | |
| CN110327431A (en) | Application and drug of the Germinatus Phragmitis extract in the drug of preparation treatment inflammation | |
| CN106420697B (en) | A kind of polymethoxyflavone, composition and its preparation are used to prevent or treat the purposes of diabetes | |
| KR20140125137A (en) | Compound comprising extracts or fractions of Potentilla genus having anti-inflammation activity | |
| KR102210646B1 (en) | Health functional food composition for promoting uric acid excretion containing cornus milk extract as an active ingredient | |
| KR102150548B1 (en) | A composition comprising mixture of the herb extract and sulfasalazine for preventing or treating colitis | |
| CN116370596B9 (en) | A Chinese medicinal composition for treating biliary tract diseases | |
| WO2013043011A2 (en) | Pharmaceutical composition containing puerariae flos extracts as active ingredients for preventing and treating endometriosis | |
| KR102146570B1 (en) | Composition for preventing, improving or treating prostate disease comprising extract of Althaea rosea as effective component | |
| Upadhyay et al. | Glossary of Dolichos biflorous-A Legume with miraculous activities | |
| KR102563878B1 (en) | Composition for preventing, improving or treating prostate disease comprising extract of Cirsium japonicum De Candole as effective component |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180525 |
|
| RJ01 | Rejection of invention patent application after publication |